Amidate is a small molecule that works as a GABA-a Receptor; Anion Channel Positive Modulator.[2] It is being used across 16 indications, with its most advanced program in Approved.[1]
Amidate is one of 398 small molecule programs targeting Obesity. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
206 competitors in Heart Failure
Amidate
Bayer Aspirin
Adriamycin
Savaysa
Xifaxan
Xylocaine
Tamiflu
Potassium Iodide
Oraverse
Neo-Synephrine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Sep 7, 1982
AMIDATE
NDA NDA018227
Sources